Post-essential Thrombocythemia Myelofibrosis Clinical Trials

8 recruiting

Post-essential Thrombocythemia Myelofibrosis Trials at a Glance

9 actively recruiting trials for post-essential thrombocythemia myelofibrosis are listed on ClinicalTrialsFinder across 6 cities in 27 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in New York, Ann Arbor, and Cleveland. Lead sponsors running post-essential thrombocythemia myelofibrosis studies include Disc Medicine, Inc, Fox Chase Cancer Center, and Bristol-Myers Squibb.

Browse post-essential thrombocythemia myelofibrosis trials by phase

Treatments under study

About Post-essential Thrombocythemia Myelofibrosis Clinical Trials

Looking for clinical trials for Post-essential Thrombocythemia Myelofibrosis? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Post-essential Thrombocythemia Myelofibrosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Post-essential Thrombocythemia Myelofibrosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

Myelodysplastic SyndromesMyelofibrosisAnemia+4 more
Disc Medicine, Inc150 enrolled24 locationsNCT05320198
Recruiting
Phase 2

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

Primary MyelofibrosisMyelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
GlaxoSmithKline68 enrolled33 locationsNCT06517875
Recruiting
Phase 3

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

MyelofibrosisPolycythemia VeraPrimary Myelofibrosis+3 more
Merck Sharp & Dohme LLC400 enrolled21 locationsNCT06351631
Recruiting

Registry Platform Myelofibrosis and Anemia

MyelofibrosisAnemiaPrimary Myelofibrosis+4 more
iOMEDICO AG200 enrolled1 locationNCT06976918
Recruiting
Phase 2

Study of Canakinumab in Patients With Myelofibrosis

Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisET-MF+2 more
John Mascarenhas14 enrolled8 locationsNCT05467800
Recruiting
Phase 3

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum399 enrolled207 locationsNCT03165734
Recruiting

A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Bristol-Myers Squibb137 enrolled3 locationsNCT06073847
Recruiting
Phase 1

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Chronic Myelomonocytic LeukemiaPolycythemia VeraPrimary Myelofibrosis+3 more
Fox Chase Cancer Center24 enrolled1 locationNCT06218628
Recruiting

Asian Myeloproliferative Neoplasm (MPN) Registry

Myeloproliferative NeoplasmPolycythemia VeraPrimary Myelofibrosis+5 more
The University of Hong Kong1,000 enrolled1 locationNCT05882773